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A 47-year-old man with an elevated prostate-specific antigen
(PSA) level of 11.6 μg/l underwent transrectal biopsies
confirming a Gleason 9 prostatic adenocarcinoma. 18F-
Fluorocholine integrated positron emission tomography
(PET)/MRI revealed a hypermetabolic lesion (maximum
standardized uptake value: 9.3) in the right posterolateral
peripheral zone, corresponding to a hyposignal in MRI T2-
weighted images (reoriented oblique axial slices). A 9-mm
right internal iliac lymph node was noted on MRI, which was
very 18F-fluorocholine avid. Pathological results from pros-
tatectomy and pelvic lymph node dissection confirmed the
presence of neoplasia in both the same prostate region and
lymph node. All other resected lymph nodes were negative.
Integrated PET/MRI is receiving growing interest in
oncology, particularly for imaging of head and neck, breast
and prostate cancers, where CT has some limitations [1].
During the last decade, 18F-fluorocholine has been studied
as a promising tracer in patients with newly diagnosed
prostate cancer and in patients with rising PSA after initial
treatment [2]. MRI allows excellent anatomical localization
of 18F-fluorocholine abnormal prostatic uptake, and extrac-
apsular extension is easily assessed on the prostate MRI
specific acquisitions obtained the same day.
Classically, 1 cm has been considered the cutoff size
between benign and malignant lymph nodes [3]. However,
PET/CT imaging has showed that this cutoff has some
limitations [4]. Some infracentimetric lymph nodes that
look benign on CT or MRI may appear hypermetabolic on
PET and thus become suspicious.
With the growing concerns about the ionizing radiations
in medical imaging [5], integrated PET/MRI has the
potential to become the modality of choice for prostate
cancer imaging.
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